Creative Medical Technology - שינוי בהכנסות משנה לשנה ב-12 החודשים האחרונים CELZ

The specifics of Creative Medical Technology (CELZ) require costly cryogenic transportation in nitrogen to preserve cells. Meanwhile, the commercial impact of immunotherapy is expected in the long term, as current costs are already priced in by the market. The business is scaling its regenerative patents through clinic licensing. The year-over-year sales trajectory over the trailing four quarters demonstrates revenue dynamics, where the current mark equals -49.90.

For a portfolio manager, this indicator serves as a market noise filter, measuring revenue growth rates over a rolling twelve-month period to identify the actual trajectory of business development. By analyzing the year-over-year sales growth trajectory over the TTM, the investor assesses the effectiveness of Creative Medical Technology (CELZ) patent commercialization in the field of regenerative medicine and the potential for scaling their mass production.